C oronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by the respiratory symptoms implicit in the name severe acute respiratory syndrome. Still, with the increasing number of cases, it has also been linked to nonpulmonary targets, including cardiac, gastrointestinal, skin, renal, and neurologic manifestations (1-5). Venous thromboembolism has also been shown to be an important cause of morbidity and mortality in patients with COVID-19, both in the general inpatient and in the intensive care unit (ICU) setting, and even in patients receiving therapeutic anticoagulation (6-8). For example, in one autopsy series, unsuspected deep vein thrombosis was found in the majority of patients with COVID-19, and pulmonary embolism was the cause of death in one-fourth of these patients (9). Arterial thrombosis has also been reported within coronary arteries (6,10) and within the brain (6,11) in patients with COVID-19. There have also been case reports regarding mesenteric (12-14) and aortoiliac (6,12) thrombosis. In our practice, in a COVID-19 hotspot, where at its peak (April 12, 2020) our hospital system had 1194 inpatients with diagnosed COVID-19, we have observed an increased number of patients presenting with lowerextremity ischemia and extensive arterial thromboses during the current pandemic. These patients typically presented to the emergency department with new symptoms of leg pain, coldness, discoloration, and ulceration, and they underwent lower-extremity CT angiography. Diagnostic work-ups in many of these patients showed them to be positive for the SARS-CoV-2 virus. With growing evidence of coagulopathy or vasculopathy (15) in patients with COVID-19, we investigated whether these cases were also due to COVID-19-related thrombosis. The goal of